Halozyme Therapeutics, Inc. - Common Stock (HALO)
Healthcare › Biological Products, (No Diagnostic Substances)
Price History
Feb 9, 2026 — Jul 6, 2026Investment Snapshot
- Trading 355% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 7/9 — financially strong with improving fundamentals
- Strong ROE of 277.1% with 46.0% net margin
- Revenue growing at 38% annually
Halozyme Therapeutics, Inc. - Common Stock (HALO) is a Healthcare company operating in Biological Products, (No Diagnostic Substances), listed on the NASDAQ , with a market capitalisation of $7.9 billion . Key value metrics: P/E ratio 13.0, P/B ratio 35.93, Piotroski F-Score 7 out of 9 (strong financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Halozyme Therapeutics, Inc. - Common Stock — Fundamental Analysis Summary
Halozyme Therapeutics, Inc. - Common Stock (HALO) is currently trading 355% above its Graham Number of $14.62, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries a reasonable trailing P/E ratio of 13.0x.
On financial health, HALO shows a strong Piotroski F-Score of 7/9, indicating improving fundamentals across profitability, leverage, and efficiency, and strong return on equity of 277.1% (sector average: -20.6%), and high leverage with a debt-to-equity ratio of 8.81.
StockPik's composite Value Score for HALO is 69/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
HALO reports a high gross margin of 82.7% (sector average: 39.4%) and a strong operating margin of 56.5%.
HALO shows revenue growing at 38% year-over-year, with earnings declining at 29%.